Literature DB >> 12161367

Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes.

Pellegrino Musto1, Antonietta Falcone, Grazia Sanpaolo, Michele Bisceglia, Rosella Matera, Angelo Michele Carella.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12161367

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  3 in total

Review 1.  Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?

Authors:  Mikkael A Sekeres; Alan List
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

2.  Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.

Authors:  Xionghu Yang; Nancy A Brandenburg; John Freeman; Maria Luisa Salomon; Jerome B Zeldis; Robert D Knight; Robert Bwire
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

3.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.